Zacks Investment Research lowered shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) from a buy rating to a hold rating in a research note released on Wednesday.

According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “

Separately, BidaskClub downgraded shares of Smith & Nephew SNATS from a strong-buy rating to a buy rating in a report on Tuesday, June 13th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $41.00.

Shares of Smith & Nephew SNATS (NYSE:SNN) traded down 0.15% during midday trading on Wednesday, hitting $36.52. The company had a trading volume of 383,895 shares. The company’s 50-day moving average price is $36.18 and its 200 day moving average price is $34.49. Smith & Nephew SNATS has a 12-month low of $26.97 and a 12-month high of $37.22. The company has a market capitalization of $15.99 billion, a price-to-earnings ratio of 18.59 and a beta of 0.74.

WARNING: “Smith & Nephew SNATS, Inc. (SNN) Downgraded to Hold at Zacks Investment Research” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/smith-nephew-snats-inc-snn-downgraded-to-hold-at-zacks-investment-research/1611058.html.

The company also recently declared a semiannual dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a $0.246 dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend is Thursday, October 5th.

A number of large investors have recently made changes to their positions in SNN. Paloma Partners Management Co bought a new position in Smith & Nephew SNATS in the 1st quarter valued at $200,000. Greenleaf Trust bought a new position in Smith & Nephew SNATS in the 2nd quarter valued at $207,000. RMB Capital Management LLC bought a new position in Smith & Nephew SNATS in the 1st quarter valued at $219,000. Dynamic Technology Lab Private Ltd bought a new position in Smith & Nephew SNATS in the 1st quarter valued at $224,000. Finally, HighTower Advisors LLC bought a new position in Smith & Nephew SNATS in the 1st quarter valued at $242,000. 6.36% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.